


# UPDATE ON CALCITONIN GENE-RELATED PEPTIDE MONOCLONAL ANTIBODIES



The HSE introduced a managed access protocol (MAP) for calcitonin gene-related peptide (CGRP) monoclonal antibodies (MABs) in September 2021. The aim of the MAP is to provide patients with chronic migraine who have failed three or more prophylactic treatments, with access to CGRP MABs. These are biological medicines used to prevent migraines, and include erenumab, fremanezumab and galcanezumab.

To date, the HSE have approved 42 prescribers for CGRP MABs under this protocol. By April 2023, over 1,000 patients were accessing treatment with a CGRP MAB each month under the High Tech Arrangement. The majority of these patients are female, with a mean age of 45 years.

**May 2023**

**HSE Medicines Management Programme.**